|
EIF2S1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.44829994850471E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.53220000020937E-07 |
| Normal-vs-Stage2 |
9.600900E-03 |
| Normal-vs-Stage3 |
2.6456999924207E-09 |
| Normal-vs-Stage4 |
1.31260002866895E-09 |
| Stage1-vs-Stage2 |
9.979600E-02 |
| Stage1-vs-Stage3 |
1.421790E-01 |
| Stage1-vs-Stage4 |
3.323700E-02 |
| Stage2-vs-Stage3 |
1.183780E-02 |
| Stage2-vs-Stage4 |
5.801000E-03 |
| Stage3-vs-Stage4 |
5.263400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.94179996713262E-09 |
| Normal-vs-AfricanAmerican |
4.176100E-04 |
| Normal-vs-Asian |
3.554299999875E-07 |
| Caucasian-vs-AfricanAmerican |
9.069200E-01 |
| Caucasian-vs-Asian |
6.073000E-01 |
| AfricanAmerican-vs-Asian |
6.375200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.74480005391098E-09 |
| Normal-vs-Female |
1.06100000007991E-07 |
| Male-vs-Female |
1.097190E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.42619999998761E-06 |
| Normal-vs-Age(41-60Yrs) |
8.30159996301205E-09 |
| Normal-vs-Age(61-80Yrs) |
4.28600000046409E-07 |
| Normal-vs-Age(81-100Yrs) |
1.956490E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.841010E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.996000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.215600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.376000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.452800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.629400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.182600E-01 |
| Classical-VS-Follicular |
7.969000E-01 |
| Classical-VS-Other |
1.286990E-01 |
| Classical-VS-Normal |
4.08920000083413E-08 |
| Tall-VS-Follicular |
1.077560E-01 |
| Tall-VS-Other |
4.640200E-01 |
| Tall-VS-Normal |
4.15589999969157E-07 |
| Follicular-VS-Other |
2.029200E-01 |
| Follicular-VS-Normal |
6.02509999999556E-05 |
| Other-VS-Normal |
5.164300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.26850000006884E-07 |
| Normal-vs-N1 |
1.407099992079E-09 |
| N0-vs-N1 |
3.150200E-02 |
|
|
